Total Payments
$3,360
2024 Payments
$402.74
Companies
22
Transactions
172
Medicare Patients
2,557
Medicare Billing
$314,552
Payment Breakdown by Category
Food & Beverage$3,293 (98.0%)
Education$66.26 (2.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,293 | 169 | 98.0% |
| Education | $66.26 | 3 | 2.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $508.04 | 19 | $0 (2024) |
| Merck Sharp & Dohme LLC | $436.98 | 25 | $0 (2024) |
| Allergan, Inc. | $404.11 | 33 | $0 (2020) |
| ViiV Healthcare Company | $347.29 | 18 | $0 (2024) |
| Melinta Therapeutics, LLC | $211.94 | 8 | $0 (2024) |
| Insmed, Inc. | $207.91 | 6 | $0 (2023) |
| Theravance Biopharma, Inc. | $192.21 | 13 | $0 (2018) |
| Janssen Biotech, Inc. | $182.64 | 11 | $0 (2021) |
| Shire North American Group Inc | $143.20 | 6 | $0 (2018) |
| Shionogi Inc | $139.68 | 6 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $402.74 | 16 | Gilead Sciences, Inc. ($105.49) |
| 2023 | $204.72 | 9 | Melinta Therapeutics, LLC ($81.80) |
| 2022 | $200.14 | 9 | Shionogi Inc ($76.65) |
| 2021 | $437.04 | 17 | La Jolla Pharmaceutical Company ($79.38) |
| 2020 | $307.29 | 21 | Allergan, Inc. ($208.28) |
| 2019 | $239.36 | 15 | ViiV Healthcare Company ($67.19) |
| 2018 | $615.36 | 35 | Merck Sharp & Dohme Corporation ($111.20) |
| 2017 | $952.87 | 50 | Theravance Biopharma Inc. ($158.36) |
All Payment Transactions
172 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $19.17 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $24.45 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.21 | General |
| 10/10/2024 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $32.17 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 09/18/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $25.55 | General |
| Category: ANTIFUNGALS | ||||||
| 08/20/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: ANTIBIOTIC | ||||||
| 08/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $28.42 | General |
| 07/31/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: HIV | ||||||
| 07/02/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE, AVYCAZ | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/29/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO, DIFICID | Food and Beverage | In-kind items and services | $34.87 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/02/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $24.58 | General |
| Category: HIV | ||||||
| 04/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.87 | General |
| 03/21/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $29.11 | General |
| Category: ANTIFUNGALS | ||||||
| 02/15/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $24.77 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.99 | General |
| 02/07/2024 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $21.52 | General |
| Category: HIV | ||||||
| 12/15/2023 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $24.75 | General |
| Category: ANTIFUNGALS | ||||||
| 09/07/2023 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $26.55 | General |
| Category: ANTIFUNGALS | ||||||
| 08/23/2023 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $15.32 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/11/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.93 | General |
| 05/04/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: Respiratory | ||||||
| 04/22/2023 | Melinta Therapeutics, LLC | Vabomere (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $30.50 | General |
| Category: ANTIBIOTICS | ||||||
| 03/23/2023 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $17.48 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/09/2023 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $22.89 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 01/12/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.63 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 609 | 845 | $265,250 | $76,508 |
| 2022 | 7 | 552 | 733 | $165,738 | $62,402 |
| 2021 | 9 | 618 | 915 | $183,155 | $76,455 |
| 2020 | 7 | 778 | 1,134 | $237,480 | $99,187 |
Total Patients
2,557
Total Services
3,627
Medicare Billing
$314,552
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 124 | 205 | $66,625 | $19,192 | 28.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 114 | 119 | $59,500 | $16,192 | 27.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 142 | 244 | $61,000 | $15,243 | 25.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 82 | 83 | $33,200 | $8,452 | 25.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 76 | 115 | $20,700 | $7,886 | 38.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 39 | 47 | $11,750 | $4,697 | 40.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $7,225 | $2,955 | 40.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $5,250 | $1,891 | 36.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 82 | 84 | $34,300 | $13,000 | 37.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 143 | 227 | $34,841 | $12,801 | 36.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 101 | 150 | $33,012 | $12,000 | 36.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 94 | 97 | $27,325 | $10,270 | 37.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 89 | 127 | $22,860 | $9,031 | 39.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 29 | 34 | $8,500 | $3,530 | 41.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $4,900 | $1,769 | 36.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 173 | 331 | $46,671 | $19,009 | 40.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 73 | 79 | $30,810 | $12,603 | 40.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 89 | 150 | $30,450 | $12,343 | 40.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 98 | 159 | $25,065 | $11,586 | 46.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 104 | 106 | $28,090 | $11,501 | 40.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 38 | 46 | $10,204 | $4,880 | 47.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 20 | 20 | $6,582 | $2,318 | 35.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 12 | 12 | $4,803 | $2,010 | 41.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 11 | 12 | $480.00 | $204.18 | 42.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 176 | 324 | $65,772 | $27,332 | 41.6% |
About Dr. Mukul Patharkar, M.D
Dr. Mukul Patharkar, M.D is a Infectious Disease healthcare provider based in Fayetteville, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/09/2007. The National Provider Identifier (NPI) number assigned to this provider is 1922157338.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mukul Patharkar, M.D has received a total of $3,360 in payments from pharmaceutical and medical device companies, with $402.74 received in 2024. These payments were reported across 172 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($3,293).
As a Medicare-enrolled provider, Patharkar has provided services to 2,557 Medicare beneficiaries, totaling 3,627 services with total Medicare billing of $314,552. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Infectious Disease
- Location Fayetteville, GA
- Active Since 01/09/2007
- Last Updated 04/17/2017
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1922157338
Products in Payments
- VIBATIV (Drug) $286.27
- DALVANCE (Drug) $262.56
- AVYCAZ (Drug) $173.31
- TRIUMEQ (Drug) $164.26
- Fetroja (Drug) $139.68
- Arikayce (Drug) $126.88
- Hizentra (Biological) $116.62
- Genvoya (Drug) $112.09
- CUVITRU (Biological) $108.39
- Rezzayo (Drug) $105.96
- DOVATO (Drug) $103.91
- ISENTRESS (Drug) $93.36
- ZERBAXA (Drug) $88.53
- XERAVA (Drug) $79.38
- DIFICID (Drug) $69.71
- PIFELTRO (Drug) $69.05
- PREZISTA (Drug) $63.50
- SYMTUZA (Drug) $61.80
- Vabomere (Drug) $55.55
- Xerava (Drug) $34.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Fayetteville
Dr. Chukwuemeka Chima, Md, MD
Infectious Disease — Payments: $47,564
Infectious Disease $47,564
Dr. James Newton, M.d, M.D
Infectious Disease — Payments: $30,570
Infectious Disease $30,570
Carlos Lewis, D.o, D.O
Infectious Disease — Payments: $6,035
Infectious Disease $6,035
Dr. Gweneth Francis, D.o, D.O
Infectious Disease — Payments: $3,820
Infectious Disease $3,820
Dr. Renaldo Neeley, Md, MD
Infectious Disease — Payments: $1,865
Infectious Disease $1,865
Ameera Siddiqi, Md, MD
Infectious Disease — Payments: $1,077
Infectious Disease $1,077